Molecule Life Cycle Managment; POM to P to GSL

Event details

12th May 2011
Notified soon

About the event


The considerable decline in the number of approved POM-P switches in recent years, despite early success highlights the need to address the issue. SMi Group provides a CPD accredited masterclass which helps those who want to find out more about making the switch from POM-P and P-GSL and enables industry professionals to discuss the challenges and develop strategies for them.


This event covers a broad range of topics and provides a comprehensive survey and in-depth analysis of the history of POM-P switches, switches that have failed and succeeded and the lessons that can be learnt from those successes and failures. The masterclass is headed by an expert who has in-depth knowledge and experience in the pharmaceutical industry, who has created Janssen OTC Division which oversaw the launch of the first ever POM to P switch Imodium OTC.  By 1991 Janssen had also switched three other molecules in the therapy areas of hayfever, threadworm and thrush accounting for more than 50% of all switches at that time. In 1992 he left Janssen as Sales and Marketing Director responsible for both the prescription and OTC businesses, to set up his own company AHA offering POM to P expertise to the Pharmaceutical Industry.


Understanding why the numbers of POM-P switches have fallen and how to address the balance is all the more necessary as NHS spending cuts take effect which may potentially lead GPs to reduce prescribing and further promote self-care.  The masterclass will explore various case studies to ensure that lessons can be learned from past successes and failures. 


Benefits of attending SMi’s CPD accredited masterclass, Molecule Life Cycle Management: POM to P to GSL - Switching Patients to Consumers 2011:


Upon completion of this Masterclass, through a combination of presentations and interactive discussion, you will:


  • Acquirean understanding of the current legalisation and
  • Gainan insight from previous unsuccessful POM-P switches and how to avoid their pitfalls
  • Examinethe changing regulatory switch environment
  • Discussthe lessons learned for future switching
  • Assess the business model of the POM-P process
  • Learnfrom an extremely experienced industry professional with over three decades of pharmaceutical experience.


For further information and the opportunity to register online please visit;

Exhibitor information


The aim of SMi is Linking Business with Information through the delivery of high quality business to business information services. Our overriding advantage is our flexibility and ability to respond quickly to the requirements and needs of all our customers, ensuring that all SMi products are highly relevant, innovative and timely.


The SMi Group is a world leader in business to business information. Within the past year thousands of senior executives from blue chip companies benefited from SMi's highly targeted conferences, workshops and masterclasses.


As a market research based organisation, SMi takes pride in the quality of its programmes and documentation, ensuring that they are brought to the attention of the key decision makers in each industry sector in which it operates. We cultivate and maintain strong industry contacts to ensure that we are informed of all pending changes in government and regulatory policy, and we regard our relationships with speakers, delegates and subscribers as an investment for the future.